Frontier Pharma: Type 2 Diabetes Mellitus – Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline

The disease is progressive: patients standard of living deteriorate over time and the symptoms worsen, meaning more complex treatment regimens are required over time. The complexity of the treatment means there is a high diversity of marketed products. In recent years new drug types have been great commercial successes and reached blockbuster status.

This alongside the financial cost of type 2 diabetes to healthcare providers has led to significant investment in R&D on therapeutics in this area.

Scope

– Requirement for new types of therapeutics to add to already complex treatment algorithms for severe T2DM
– What are the most important etiological risk factors and pathophysiological processes implicated in T2DM?
– What is the current treatment algorithm?
– How effective are current therapies for these indications, and how does this impact prognosis? What are the side effects associated with these treatments?
– The T2DM pipeline is dominated by G-protein-coupled receptors (GPCRs) and protein kinases
– Which molecule types and molecular targets are most prominent in the T2DM pipeline?
– Which first-in-class targets are most promising?
– How does the level of first-in-class innovation change within different target classes?
– How does first-in-class target diversity differ by stage of development and molecular target class?
– The deals landscape is active and dominated by products that target GPCRS and protein kinases
– Which molecular types/molecular target groups attract the highest deal values?
– How has deal activity fluctuated over the past decade?
– Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons to buy

– Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, and diagnosis and treatment options.
– Identify leading products and key unmet needs within the market.
– Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
– Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets identified in the pipeline for T2DM. Promising early-stage first-in-class targets are reviewed in greater detail.
– Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.